Article Details
Retrieved on: 2024-10-31 15:15:56
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Axonis' development in MedTech for epilepsy, emphasizing their work on enhancing the Chloride potassium symporter 5 (KCC2) to improve treatment outcomes. This aligns with tags such as epilepsy, neurology, and gene therapy.
Article found on: www.outsourcing-pharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here